Shares of AbbVie (ABBV) were lower by 2.26% to $65.34 on Wednesday morning, after the U.S. Patent and Trade Mark Office's Patent Trial and Appeals Board ruled Tuesday in favor of a challenge from Coherus BioScience (CHRS) relating to AbbVie's rheumatoid arthritis drug Humira.
The drug is responsible for more than 60% of AbbVie's top line, Barron's noted, and has been pressured by similar products overseas. The company's patent is set to expire soon, allowing challenges from competitors.
Coherus stock was climbing by 8.39% to $23.90 on heavy trading volume this morning.
Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.